Angiotensin Converting Enzyme – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
The Angiotensin Converting Enzyme pipeline drugs market research report outlays comprehensive information on the Angiotensin Converting Enzyme targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, Infectious Disease, and Musculoskeletal Disorders which include indications of Hypertension, Congestive Heart Failure (Heart Failure), Relapsing Remitting Multiple Sclerosis (RRMS), Coronavirus Disease 2019 (COVID-19), and Osteoarthritis. It also reviews key players involved in Angiotensin Converting Enzyme targeted therapeutics development with respective active and dormant or discontinued projects.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Angiotensin Converting Enzyme | Therapy Area |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Companies |
|
||
| Key Molecule Type |
|
||
Scope
- The report provides a snapshot of the global therapeutic landscape for Angiotensin Converting Enzyme
- The report reviews Angiotensin Converting Enzyme targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Angiotensin Converting Enzyme targeted therapeutics and enlists all their major and minor projects
- The report assesses Angiotensin Converting Enzyme targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Angiotensin Converting Enzyme targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Angiotensin Converting Enzyme Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Angiotensin Converting Enzyme development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Players
AFT Pharmaceuticals LtdAngioDesign UK Ltd
CardioPharma Inc
Ethicare GmbH
HLS Therapeutics Inc
Jiangxi Shimei Pharmaceutical Co Ltd
Les Laboratoires Servier SAS
Medlab Clinical Ltd
Mor Research Applications Ltd
Proveca Ltd
SyneuRx International (Taiwan) Corp
Transparency Life Sciences LLC
University of Cape Town
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pharmaceuticals reports